Exelixis, Inc. - Common Stock (NQ:EXEL)

58.42 +0.03 (+0.06%)

Delayed Quote Updated: 9:57 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 28, 2021

Gainers Intellia Therapeutics (NASDAQ:NTLA

Via Benzinga

Mid-Day Market Update: Crude Oil Down Over 1%; Intellia Therapeutics Shares Jump ↗

June 28, 2021

Midway through trading Monday, the Dow traded down 0.52% to 34,253.86 while the NASDAQ rose 0.72% to 14,463.56. The S&P also fell, dropping 0.01% to 4,280.50. The U.S. has the...

Via Benzinga

Topics Stocks

Here's Why Exelixis Stock Is Dropping Today ↗

June 28, 2021

The company reported successful clinical trial results, but investors were still disappointed.

Via The Motley Fool

44 Stocks Moving In Monday's Mid-Day Session ↗

June 28, 2021

Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software...

Via Benzinga

Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer ↗

June 28, 2021

Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 28, 2021

Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 62.0% to $143.91 during Monday's pre-market session. The company's market cap stands at $9.8 billion....

Via Benzinga

The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus ↗

June 27, 2021

Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment. Eli Lilly and Company (NYSE: LLY) stood out among big...

Via Benzinga

Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence

June 18, 2021

From Exelixis, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 ↗

June 15, 2021

Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an...

Via Benzinga

Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors

June 14, 2021

From Exelixis, Inc.

Via Business Wire

Unheeding Markets ↗

June 10, 2021

Today oil prices rose over $70.

Via Talk Markets

Here's What Crushed Exelixis' Earnings ↗

June 06, 2021

R&D spending is hurting earnings, but long-term investors shouldn't be worried.

Via The Motley Fool

Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma

June 04, 2021

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma

June 04, 2021

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Positive Phase 2 Results for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021

June 04, 2021

From Exelixis, Inc.

Via Business Wire

2 Top Biotech Stocks to Buy Right Now ↗

May 30, 2021

One is growing revenue. And the other may soon launch its first product.

Via The Motley Fool

3 Cheap Pharmaceutical Stocks to Grab Now ↗

May 28, 2021

The pharmaceutical industry has been the beneficiary of significant investor attention amid the COVID-19 pandemic as society turned to its products to fight the coronavirus.

Via Talk Markets

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June

May 26, 2021

From Exelixis, Inc.

Via Business Wire

Sterling At Five-Year High ↗

May 25, 2021

Today markets are mixed because of currency factors, with sterling bullishness against the dollar and the euro.

Via Talk Markets

The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal ↗

May 25, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company...

Via Benzinga

Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients ↗

May 25, 2021

Exelixis Inc (NASDAQ: EXEL) has announced results from cohort 6 of the COSMIC-021 Phase 1b trial evaluating Cabometyx (cabozantinib) in combination...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

May 24, 2021

Gainers OptiNose (NASDAQ:OPTN) stock rose...

Via Benzinga

Exelixis Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

May 24, 2021

From Exelixis, Inc.

Via Business Wire

Is Exelixis a Buy? ↗

May 22, 2021

Revenue growth will probably accelerate soon, but it might not be enough.

Via The Motley Fool

What Investors Should Look for With Exelixis, DermTech, and Teladoc Health ↗

May 21, 2021

All three healthcare stocks could have solid growth prospects.

Via The Motley Fool

Why Is GlaxoSmithKline Selling Its Income Stream to Royalty Pharma? ↗

May 09, 2021

Apparently, up-front capital is better than royalties on drugs the pharma doesn't have control over.

Via The Motley Fool

Exelixis Inc (EXEL) Q1 2021 Earnings Call Transcript ↗

May 07, 2021

EXEL earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Exelixis: Q1 Earnings Insights ↗

May 06, 2021

Shares of Exelixis (NASDAQ:EXEL) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 52.63% over the past year...

Via Benzinga

Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update

May 06, 2021

From Exelixis, Inc.

Via Business Wire

Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma’s First-in-Class Humanized Antibody Program Against a Novel Oncology Target

May 04, 2021

From Exelixis, Inc.

Via Business Wire

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.